At a glance
- Originator Tanabe Seiyaku
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 28 Jul 1998 No-Development-Reported for Hypercholesterolaemia in Japan (Unknown route)
- 25 Jan 1995 Phase-II clinical trials for Hypercholesterolaemia in Japan (Unknown route)